Tarsons Products Limited — PPTs, 15-02-2025: Investor Presentation

**Financial Highlights**: Tarsons Products Limited reported standalone revenues of Rs. 76.2 crore for Q3FY25, marking a 23.3% year-on-year increase. Consolidated revenues reached Rs. 95.7 crore during the same period, up from Rs. 76.2 crore in Q3FY24. For 9MFY25, standalone revenue stood at Rs. 221.1 crore, a 16% increase from Rs. 190.7 crore in 9MFY24, with consolidated revenues at Rs. 279.7 crore.

**Strategic Initiatives and Growth Drivers**: The company's Panchla facility has commenced commercial production, contributing positively to their growth strategy. The expansion of product offerings coupled with rising inquiries in both domestic and international markets drives a positive outlook.

**Business Developments**: The acquisition of Nerbe, which adds Rs. 59 crore to consolidated revenues for 9MFY25, is expected to enhance market reach and product capabilities.

**Market Position and Competitive Advantage**: Tarsons is recognized for its robust product portfolio and quality manufacturing, positioning it among the top three players in India’s labware market. Its diverse distribution network and established relationships enhance its competitive edge.

**Investor Implications**: With ongoing demand recovery and expansion plans, Tarsons holds significant potential for growth, warranting close attention from investors. The company’s operational efficiencies and strategic developments indicate a favorable trajectory in the highly fragmented labware market.